Scientific Reports (Mar 2023)

Use of dual genomic sequencing to screen mitochondrial diseases in pediatrics: a retrospective analysis

  • Teng-Hui Wu,
  • Jing Peng,
  • Li Yang,
  • Yan-Hui Chen,
  • Xiu-Lan Lu,
  • Jiao-Tian Huang,
  • Jie-Yu You,
  • Wen-Xian Ou-Yang,
  • Yue-Yu Sun,
  • Yi-Nan Xue,
  • Xiao Mao,
  • Hui-Ming Yan,
  • Rong-Na Ren,
  • Jing Xie,
  • Zhi-Heng Chen,
  • Victor-Wei Zhang,
  • Gui-Zhen Lyu,
  • Fang He

DOI
https://doi.org/10.1038/s41598-023-31134-5
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Mitochondrial diseases (MDs) were a large group multisystem disorders, attributable in part to the dual genomic control. The advent of massively sequencing has improved diagnostic rates and speed, and was increasingly being used as a first-line diagnostic test. Paediatric patients (aged < 18 years) who underwent dual genomic sequencing were enrolled in this retrospective multicentre study. We evaluated the mitochondrial disease criteria (MDC) and molecular diagnostic yield of dual genomic sequencing. Causative variants were identified in 177 out of 503 (35.2%) patients using dual genomic sequencing. Forty-six patients (9.1%) had mitochondria-related variants, including 25 patients with nuclear DNA (nDNA) variants, 15 with mitochondrial DNA (mtDNA) variants, and six with dual genomic variants (MT-ND6 and POLG; MT-ND5 and RARS2; MT-TL1 and NARS2; MT-CO2 and NDUFS1; MT-CYB and SMARCA2; and CHRNA4 and MT-CO3). Based on the MDC, 15.2% of the patients with mitochondria-related variants were classified as “unlikely to have mitochondrial disorder”. Moreover, 4.5% of the patients with non-mitochondria-related variants and 1.43% with negative genetic tests, were classified as “probably having mitochondrial disorder”. Dual genomic sequencing in suspected MDs provided a more comprehensive and accurate diagnosis for pediatric patients, especially for patients with dual genomic variants.